Susan Andrea Gutierrez-Rubio

Dr. Susan Andrea Gutierrez-Rubio


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
LRLidia Ariadna Rubio-Chavez
Lidia Ariadna Rubio-Chavez
RRRoberto Carlos Rosales-Gomez
Roberto Carlos Rosales-Gomez
KRKeren-Hapuc Lilian Rubio-Chavez
Keren-Hapuc Lilian Rubio-Chavez
JRJulia Leonila Ramos-Nuñez
Julia Leonila Ramos-Nuñez
TGTeresa Arcelia Garcia-Cobian
Teresa Arcelia Garcia-Cobian
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
Background: Adiponectin, encoded by the ADIPOQ gene, is produced mainly by adipose tissue, and meaning as a metabolic and immunological regulator. The polymorphism rs822396 in ADIPOQ gene was previously associated with diabetes mellitus type 2, hypertension, and metabolic syndrome components in Caucasian and Asiatic populations. The aim was to evaluate the association of the rs822396 polymorphism of the ADIPOQ gene with anthropometric, clinical, and biochemical alterations related to the metabolic syndrome in the Mexican population. Materials and Methods: Measurements, as well as peripheral blood for DNA extraction, were obtained from 434 participants from Mexico. The rs822396 polymorphism genotyping was performed by polymerase chain reaction–restriction fragment length polymorphism. Statistical analysis was made with IBM-SPSSv20. Results: The rs822396G allele frequency was 22.1% in the Mexican population analyzed. In this study were detected differences according to G allele or GG genotype with the highest means, including body mass index (BMI), waist circumference (WC), body fat percentage, visceral fat, systolic arterial tension, glucose levels, triglyceride levels, total cholesterol (TC) levels, very low-density lipoprotein, alanine aminotransferase, and aspartate aminotransferase and with triglycerides/glucose index. Significant differences were found with increased risk in the dominant model (AG/GG) of anthropometric, clinical, and biochemical alterations with regard to metabolic syndrome as the BMI [odds ratio (OR) = 2.19], WC (OR = 2.00), waist/hip index (OR = 1.65), body fat percentage (OR = 2.76), visceral fat (OR = 1.84), glucose levels (OR = 1.95), triglyceride levels (OR = 2.75), TC levels (OR = 1.63), high-density lipoprotein (OR = 1.86), and insulin resistance surrogated by the Triglyceride/glucose index (OR = 2.64). Conclusion: The rs822396 polymorphism of the ADIPOQ gene seems to be a risk factor for obesity and metabolic alterations with regard to the metabolic syndrome in the Mexican population.

2 April 2025 in Life
Verified
Journal Article
Open access
PDF file
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
EMEzequiel Magallón-Gastélum
Ezequiel Magallón-Gastélum
TGTrinidad García-Iglesias
Trinidad García-Iglesias
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
TCTeresa Arcelia Garcia Cobián
Teresa Arcelia Garcia Cobián
Resistin is an adipokine produced in adipose tissue with pro-inflammatory properties, whose elevation has been associated with insulin resistance and diabetes. Over the past years, significant research has explored the pathophysiological mechanisms involving resistin, utilizing various in vitro and in vivo models. Additionally, numerous clinical studies have aimed to establish a correlation between resistin and the development and progression of macrovascular and microvascular complications in type 2 diabetes. This narrative review summarizes in vitro, in vivo, and human studies published in English since the discovery of resistin in 2001 to the present, examining the role of this adipokine in the pathophysiology of macrovascular and microvascular complications in in vivo and in vitro T2D models, as well as the clinical evidence supporting its use as a biochemical marker in patients with these conditions. The results exhibit considerable heterogeneity and appear to be dependent on the experimental model or population studied. While experimental evidence supports resistin’s involvement at the cellular and molecular levels in the pathogenesis of these complications, current clinical evidence remains insufficient to justify its use as a biochemical marker for either diagnosis or prognosis. Therefore, further well-designed studies are required to elucidate resistin’s potential role in the clinical setting.

8 August 2025 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
DODiego Ortega-Pacheco
Diego Ortega-Pacheco
RGRoberto Carlos Rosales Gómez
Roberto Carlos Rosales Gómez
TCTeresa Arcelia Garcia Cobián
Teresa Arcelia Garcia Cobián
LRLidia Ariadna Rubio-Chávez
Lidia Ariadna Rubio-Chávez
AGAngélica Adriana Gutiérrez-Rubio
Angélica Adriana Gutiérrez-Rubio
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
Objective: To evaluate the predictive risk factors associated with the prevalence of metabolic syndrome (MetS) in adolescents from the western region of Mexico. Materials and Methods: An analytical cross-sectional study was conducted with a sample of 516 adolescents. Anthropometric data, blood pressure, and biochemical determinations were obtained. The diagnosis of MetS was based on the criteria proposed by de Ferranti in 2004. The triglyceride–glucose index (TyG index) was calculated, where a value >4.68 indicates insulin resistance (IR). Risk factors associated with MetS were evaluated using a logistic regression model. The statistical analysis was performed with the level of statistical significance established was p < 0.05. Results: The MetS prevalence was 17.2% among adolescents. One out of every two adolescents with obesity presented with MetS. Abdominal obesity and dyslipidemia are the most common components. Predictors of MetS included male sex, early adolescence, waist-to-height ratio (WHtR) > 0.5, increased body fat percentage, and TyG Index > 4.68 (IR). In the sex-specific analysis, a WHtR > 0.5 and IR were associated with MetS in female adolescents. In male adolescents, IR and body fat percentage were associated with MetS. The WHtR was associated with IR, and hypertriglyceridemia was associated with elevated alanine aminotransferase. Conclusions: In this study, two out of ten adolescents presented with MetS. In boys, a high prevalence of abdominal obesity, hypoalphalipoproteinemia, insulin resistance and MetS was observed. The risk of developing MetS is greater in preadolescent boys with abdominal obesity, high levels of body fat, and a TyG index > 4.68.

12 November 2025 in Diabetology
Verified
Journal Article
Open access
PDF file
ARAfrica Samantha Reynoso Roa
Africa Samantha Reynoso Roa
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio
ACAraceli Castillo-Romero
Araceli Castillo-Romero
TGTrinidad García-Iglesias
Trinidad García-Iglesias
Daniel Osmar Suárez-RicoDaniel Osmar Suárez-Rico
Daniel Osmar Suárez-Rico
TCTeresa Arcelia Garcia Cobián
Teresa Arcelia Garcia Cobián
Background/Objectives: Insulin resistance is a major public health issue in Mexico, closely linked to obesity, prediabetes, and type 2 diabetes. The euglycemic–hyperinsulinemic clamp is the diagnostic gold standard but is impractical for routine use. The triglyceride–glucose (TyG) index has been proposed as a simple alternative validated in diverse populations. We aimed to assess the utility of TyG relative to HOMA-IR and QUICKI as an early diagnostic tool in young Mexican adults. Methods: We performed an analytical cross-sectional study in young adults. Clinical, anthropometric, and fasting biochemical variables were collected to compute TyG. We compared TyG with HOMA-IR and QUICKI and evaluated diagnostic performance using receiver operating characteristic analysis to estimate area under the curve (AUC) and identify the optimal cut-off. Results: We analyzed 115 participants; 66.9% were insulin resistant by HOMA-IR, 79.1% by QUICKI, and 42.6% by TyG. TyG showed significant associations with anthropometric and biochemical measures. Diagnostic performance was good (AUC 0.707 vs. HOMA-IR; 0.960 vs. QUICKI). The optimal cut-off was 4.38, yielding sensitivity of 70.1% and specificity of 68.4% for diagnosing insulin resistance compared with HOMA-IR. Conclusions: The TyG index appears to be a useful, accessible, and cost-effective biomarker for early detection of insulin resistance in young Mexican adults. Its implementation could facilitate earlier diagnosis and prevention of cardiometabolic complications. Longitudinal, multicenter studies are warranted to establish population-specific reference values and to confirm its predictive value for adverse outcomes.

1 October 2020 in Archives of Medical Research
Verified
Journal Article
Closed access
HMHector Montoya-Fuentes
Hector Montoya-Fuentes
ARAraceli Rodriguez-Martin
Araceli Rodriguez-Martin
DPDaniel Ivan Pena-Iniguez
Daniel Ivan Pena-Iniguez
CGCesar Raul Gonzalez-Bonilla
Cesar Raul Gonzalez-Bonilla
RRRoberto Carlos Rosales-Gomez
Roberto Carlos Rosales-Gomez
SGSusan Andrea Gutierrez-Rubio
Susan Andrea Gutierrez-Rubio